Novartis announces at EAN new data for ofatumumab demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS).

Novartis announced that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology (EAN) . The data continue to demonstrate ofatumumab (OMB157) as a potential novel treatment option for patients with RMS. The safety profile was comparable to teriflunomide. Ofatumumab is a targeted B-cell therapy that, if approved, addresses a clinical unmet need as the first B-cell therapy that can be self-administered at home through an autoinjector pen. In addition to being presented virtually, the data were also published in the European Journal of Neurology, Volume 27, Supplement 1, May 2020. A post hoc analysis from the Phase III ASCLEPIOS I and II trials (n=1882) assessed the odds of patients achieving NEDA-3 with ofatumumab versus teriflunomide within the first (Month 0–12) and second year (Month 12–24) of treatment . NEDA-3 is a comprehensive composite measure commonly used to assess treatment outcomes in patients with RMS. It is defined as an absence of three measures of disease activity: relapses; disease progression, measured as 6-month confirmed disability worsening (CDW), and gadolinium enhancing (Gd+) T1 lesions. The study results showed that compared with teriflunomide, a greater proportion of patients treated with ofatumumab achieved NEDA-3 in year 1 (47.0% vs 24.5%; P<.001) and in year 2 87.8 vs 48.2 p><.001). achieving no evidence of disease activity is widely recognized as an important treatment goal for multiple sclerosis therapies said professor ludwig kappos university hospital basel. these data suggest that halting new disease activity is possible by targeted b-cell therapy in rms. a separate analysis from the aplios trial n="284)" showed ofatumumab treatment led to rapid and sustained depletion of both cd20 b- and t-cells in patients with rms. ofatumumab depleted different b- and t-cell subsets including memory b-cells and nave b-cells as well as a subset of t-cells that are known to exhibit an activated phenotype. however cd3 t-cells that do not express the cd20 receptor were largely unaffected. regulatory action for ofatumumab in the us is expected in june 2020. novartis is committed to bringing ofatumumab to patients around the world and additional regulatory filings are currently under way. about asclepios i and ii studies : the asclepios i and ii studies are twin identical design flexible duration up to 30 months double-blind randomized multi-center phase iii studies evaluating the safety and efficacy of ofatumumab 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with rms. the asclepios i and ii studies enrolled 1882 patients with ms between the ages of 18 and 55 years with an expanded disability status scale edss score between 0 and 5.52. the studies were conducted in over 350 sites in 37 countries. ofatumumab demonstrated a significant reduction in annualized relapse rate arr by 50.5 0.11 vs 0.22 and 58.5 0.10 vs 0.25 compared with teriflunomide p><.001 in both studies in asclepios i and ii respectively primary endpoint. ofatumumab showed significant reduction of both gdt1 lesions and new or enlarging t2 lesions. it significantly reduced the mean number of both gd t1 lesions 97.5 and 93.8 relative reduction in asclepios i and ii respectively both p><.001) and new or enlarging t2 lesions 82.0 and 84.5 relative reduction in asclepios i and ii respectively both p><.001). ofatumumab also showed a relative risk reduction of 34.4 p=".002)" in 3-month cdw and 32.5 p=".012)" in 6-month cdw compared with teriflunomide in pre-specified meta-analysis as defined in asclepios . ofatumumab demonstrated that it lowered neurofilament light levels in serum at the first assessment at month 3 compared with teriflunomide. there was no difference in slope of brain volume change from baseline between treatments. in a measure of 6-month confirmed disability improvement events a favorable trend was seen but this did not reach significance. the frequency of serious infections and malignancies was similar across both treatment groups and overall ofatumumab had a similar safety profile to teriflunomide. injection-related reactions injection-site reactions and upper respiratory tract infection were the most commonly observed adverse events across both treatment groups occurring in greater than 10 of patients a separate post hoc analysis demonstrated ofatumumab may halt new disease activity in rms patients . it showed the odds of achieving neda-3 no relapses no mri lesions and no disability worsening combined with ofatumumab versus teriflunomide were greater than 3-fold higher at month m 012 47.0 vs 24.5 of patients p><.001) and greater than 8-fold higher at m1224 87.8 vs 48.2 of patients p><.001). overall ofatumumab a fully human antibody targeting cd20 b-cells delivered superior efficacy and demonstrated a safety and tolerability profile with infection rates similar to teriflunomide. about aplios study the aplios study is a 12-week open-label phase ii bioequivalence study to determine the onset of b-cell depletion with ofatumumab subcutaneous monthly injections and the bioequivalence of subcutaneous administration of ofatumumab via a pre-filled syringeas used in asclepios i and iiand an autoinjector pen in patients with rms. patients were randomized according to injection device and site including the abdomen and the thigh. b-cell depletion was measured nine times over 12 weeks and gd lesion counts were assessed at baseline and at weeks 4 8 and 12. regardless of injection device or site ofatumumab 20 mg subcutaneous monthly injections resulted in rapid close to complete and sustained b-cell depletion. the proportion of patients with b-cell concentrations of><10 cells l was greater than 65 after the first injection by day 7 94 by week 4 and sustained greater than 95 at all following injections. ofatumumab treatment reduced the mean number of gd lesions from baseline 1.5 to 0.8 0.3 and 0.1 by weeks 4 8 and 12 respectively. the proportion of patients free from gd lesions at the corresponding time points were 66.5 86.7 and 94.1 respectively. see- hauser s bar-or a cohen j et al. ofatumumab versus teriflunomide in relapsing multiple sclerosis: analysis of no evidence of disease activity neda-3 from asclepios i and ii trials. eur j neurol. 2020271:261263.>